Chemopreventive Agent Development

Designs, develops, implements, and monitors research on interventions that may block, reverse, or delay the early stages of cancer. Investigates nutrients, micronutrients, natural products, pharmacologic agents, biomolecules, and vaccines from preclinical to early-phase I clinical studies. Helps investigators to bridge the gaps between biology and identifying potential targets, and between discovery of targets and agents and clinical testing in people.

Major Programs

Staff List

Grid View

Name, Email, Phone	Room	Group(s)/Office
Asefa, Wosene wosene.asefa@nih.gov 240-276-6422	5E504	Program Support Assistant \| Chemopreventive Agent Development
Biswas, Kajal, Ph.D. kajal.biswas2@nih.gov 240-276-5614	5E540	Program Officer \| Chemopreventive Agent Development
Cholewa, Brian, Ph.D. brian.cholewa@nih.gov 240-276-7545	5E446	Deputy Chief \| Chemopreventive Agent Development
Clifford, John, Ph.D. john.clifford@nih.gov 202-235-4482	5E430	Program Officer \| Chemopreventive Agent Development
Gunasekharan, Vignesh, Ph.D. vignesh.gunasekharan@nih.gov 240-276-5814	5E438	Program Officer \| Chemopreventive Agent Development
Mohammed, Altaf, Ph.D. altaf.mohammed@nih.gov 240-276-6082	5E542	Deputy Chief \| Chemopreventive Agent Development
Nalli, Ancy, Ph.D., M.S. ancy.nalli@nih.gov 202-276-5265	5E536	Program Officer \| Chemopreventive Agent Development
Sei, Shizuko, M.D. shizuko.sei@nih.gov 240-276-5005	5E452	Co-Chief \| Chemopreventive Agent Development
Shoemaker, Robert, Ph.D. robert.shoemaker@nih.gov 240-276-7077	5E454	Co-Chief \| Chemopreventive Agent Development Acting Chief \| Nutritional Science
Vlad, Anda, M.D., Ph.D. anda.vlad@nih.gov 240-276-6422	5E538	Program Officer \| Chemopreventive Agent Development

Grants

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Perkins, Susan M	Indiana University Indianapolis United States	Evaluation of the Communication Plan Early through End-of-Life (COMPLETE) Intervention	5R01CA235632-06	Brennan Streck, Ph.D., RN, M.P.H.
Permuth, Jennifer B	H. Lee Moffitt Cancer Ctr & Res Inst United States	Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology	5R37CA229810-07	Matthew Young, Ph.D.
Pfleger, Cathie M	Icahn School Of Medicine At Mount Sinai United States	A Drosophila model for Aromatase Inhibitor-induced Musculoskeletal Pain	1R21CA303409-01	Rachel Altshuler, Ph.D.
Phillips, Nicholas S	St. Jude Children'S Research Hospital United States	Cardiopulmonary function and cerebral blood flow in Hodgkin Lymphoma survivors	5R21CA280230-02	Eileen Dimond, R.N., M.S.
Pinder, Leeya F	University Of Cincinnati United States	RepurPosed AntiretrOviraL ThErapieS to EliminAte Cervical Cancer (POLESA Trial)	3R37CA284033-03S1	Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Pistilli, Emidio Edward	West Virginia University United States	Targeting Muscle Fatigability During Cachexia	5R01AR079445-04	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Pitteri, Sharon	Stanford University United States	Glycosylation and Immune Evasion in Urologic Tumors	5U01CA226051-05
Plas, Ellen Van Der	Arkansas Children'S Hospital Res Inst United States	Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia	5R37CA266135-04	Asad Umar, D.V.M., Ph.D.
Porter, Laura S	Duke University United States	Couple Communication Skills Training for Advanced Cancer	5R01CA229425-05	Brennan Streck, Ph.D., RN, M.P.H.
Pozdeyev, Nikita	University Of Colorado Denver United States	Genetic architecture of thyroid cancer and its clinical utility	5R21CA282380-02	Wendy Wang, Ph.D., M.Sc.
Prigerson, Holly Gwen	Weill Medical Coll Of Cornell Univ United States	Behavioral and Psychosocial Effects on Study Outcomes in End-Stage Cancer Treatment (BEST End-Stage Cancer Study)	5R35CA197730-11	Brennan Streck, Ph.D., RN, M.P.H.
Punnen, Sanoj	University Of Miami School Of Medicine United States	The Rigor and Clinical Utility of PSMA Enriched Extracellular Vesicles for Prostate Cancer Detection	5R01CA272766-03	Matthew Young, Ph.D.
Pyter, Leah M	Ohio State University United States	Chemotherapy-induced circadian master clock disruptions and fatigue	3R01CA270372-03S1	Marjorie Perloff, M.D.
Rajagopalan, Malolan S	Columbus Community Clinical Oncology Prg United States	Columbus NCORP RFA-CA-18-016	3UG1CA189954-11S1	Vanessa A. White, M.P.H.
Rajkumar, S Vincent	Mayo Clinic Rochester United States	Onset and biomarkers for progression of monoclonal gammopathies	5R01CA168762-11	Nicholas Hodges, Ph.D.

Chemopreventive Agent Development

On This Page

Major Programs

Staff List

Grants